Melanotan I Reconstitution Calculator

Melanotan I is the older research/development name for afamelanotide, an α-MSH analogue used clinically for erythropoietic protoporphyria (EPP) as an implanted product; current literature discusses afamelanotide as the approved therapy for EPP and distinguishes it from investigational oral alternatives such as dersimelagon and bitopertin (human clinical). It is not an approved general-purpose tanning drug; the clinical evidence and approved use are centered on phototoxicity reduction in EPP, not cosmetic pigmentation (human clinical).

It activates melanocortin signaling, increases eumelanin production, and can increase skin pigmentation without requiring the same amount of UV exposure that normally drives tanning (human clinical/mechanistic). In lighter skin types, clinical work reported increased skin melanin and measurable sunburn protection after repeated dosing cycles, which is why it was developed as a photoprotective therapy rather than a bodybuilding/cosmetic drug (human clinical).

Yes in practice: afamelanotide is the therapeutic α-MSH analogue historically referred to as Melanotan I or NDP-α-MSH in the literature (human clinical). Modern clinical papers use the name afamelanotide and describe it as the only approved treatment for EPP, with real-world improvements in quality of life, light tolerance, and reduction in phototoxic reactions (human clinical).

Human evidence supports parenteral/depot delivery, not oral use, for Melanotan I/afamelanotide (human clinical/pharmacokinetic). The corpus includes subcutaneous dosing history, controlled-release implant work, and depot formulation research for Melanotan I, while newer orally available melanocortin agonists such as dersimelagon are discussed as distinct next-generation nonpeptidic agents rather than oral Melanotan I itself (human clinical). Community use of reconstituted subcutaneous Melanotan I exists (community protocol), but the clinically established route is implant-based afamelanotide rather than DIY injections.

For EPP, real-world data show clinically meaningful improvement in light tolerance while on treatment, with median phototoxic burn tolerance time increasing substantially during therapy (human clinical). Older tanning/photoprotection studies used repeated daily subcutaneous cycles over 3 consecutive months, while modern medical use is intermittent long-term implant therapy under specialist supervision for EPP (human clinical). For cosmetic use, there is no validated long-term safety protocol in this corpus; practitioner/community cycles are usually time-limited (community protocol), but that is not equivalent to approved medical use.

Melanotan I/afamelanotide is the better-studied medical compound for photoprotection and EPP, with human clinical efficacy data and therapeutic positioning (human clinical). Melanotan II is a different melanocortin analogue more often linked in the corpus to unregulated use and adverse-event case reports including priapism, oral pigmentation changes, eruptive/dysplastic nevi, melanoma-associated case reports, and social-media-driven misuse concerns (case report/observational) [not cited inline because not needed for Melanotan I-specific comparison]. Practically: Melanotan I has a legitimate therapeutic lane; Melanotan II is mainly a harm-signal compound in this corpus.

Evidence in children is very limited but not zero: a case report describes afamelanotide treatment in a 9-year-old child with EPP, showing pediatric use exists at specialist level for severe disease (case report). There is no pregnancy or breastfeeding safety dataset in this corpus for Melanotan I, so risk-benefit decisions in those settings are unresolved and should be treated as unknown rather than assumed safe (evidence gap). For non-EPP cosmetic use in special populations, there is no human safety framework here beyond practitioner caution (practitioner consensus).

Afamelanotide is a peptide and peptide stability matters: forced-degradation work showed afamelanotide degrades under acidic, basic, neutral, oxidative, UV, and heat stress, generating multiple degradation products (analytical/stability). Practical implication: protect from heat, light, and prolonged room-temperature exposure; avoid casual car storage, sun exposure, and repeated warm/cold cycling (practitioner consensus informed by stability data). If using compounded or reconstituted injectable product outside formal medical care, short refrigerated storage after mixing is standard community practice, but exact beyond-use dating depends on formulation and sterility controls rather than the peptide alone (community protocol).

It can increase pigmentation, but using it as a license for deliberate UV overexposure is not supported by the medical literature (human clinical). In EPP, the goal is improved light tolerance and fewer phototoxic reactions, not tanning maximization (human clinical). Community users often combine it with UV for faster color development (community protocol), but that shifts risk toward UV injury and defeats the main photoprotective rationale of the compound.